Denali Therapeutics | LinkedIn (original) (raw)

About us

Denali Therapeutics is dedicated to defeating neurodegenerative diseases by breaking through historical barriers in scientific research and clinical development in order to deliver safe and effective medicines to patients and families. Our scientific approach is based on three core principles: rigorous assessment of genetic targets, engineering brain delivery, and using biomarkers to guide development. Our team thrives in a work environment that is scientifically driven, impact-focused, supportive, and collaborative. Our ability to have a positive impact on people’s lives is directly related to the trust we have in each other and our ability to unify our diverse backgrounds and experience behind our purpose to defeat degeneration.

Industry

Biotechnology Research

Company size

201-500 employees

Headquarters

South San Francisco, California

Type

Public Company

Founded

2015

Specialties

Biotechnology, Neurodegenerative Disease, Neurodegeneration, and Pharmaceuticals

Locations

Employees at Denali Therapeutics

Updates

We reported our third quarter financial results and business highlights. Read our press release here: https://lnkd.in/gFC_RC8Y
Thank you to Cure Sanfilippo Foundation for bringing everyone together at ADVANCE 2024! We appreciate the opportunity to share our work in MPS IIIA and learn from the day-to-day experiences of the inspiring families and experts in this community.
Day 2 of ADVANCE 2024 is underway. It's packed with even more Sanfilippo-specific presentations from the world's experts and insights from the families living with Sanfilippo Syndrome. Join us! Register at www.ADVANCESanfilippo.com to access the event.Glenn O'Neill, Cara O'Neill, Robin LeWinter, Angelica Cordoba Claros PhD., Jessica Haywood, Jonathan Acevedo, Rafael A. Badell-Grau, PhD, Nadja Zeltner, Patricia Dubot, Steven Gray, Philip Gordts, PhD, Lynda Polgreen, Julie Tuccillo-Stracener PharmD, BCPPS, Michelina Iacovino, Heather Lau MD MS, simon jones, Ana-Claire Meyer, Kim Ramsey
We had the pleasure of attending Project Alive's Family Fair this past weekend to connect with individuals, families and advocates. Hearing from those who live with Hunter syndrome every day helps guide our work and is truly motivating. A huge thank you to Project Alive for hosting this event and providing a special opportunity to meaningfully connect with the community.
Advancing Rare Disease Therapies Through an FDA Rare Disease Innovation Hub was the topic of a public meeting convened today by the Reagan-Udall Foundation for the FDA, in collaboration with FDA Rare Disease Innovation Hub. Our Chief Medical Officer Carole Ho had the honor of speaking about key challenges in drug development for rare diseases and opportunities to collaborate with patient advocates, academic researchers, industry colleagues, and FDA to forge a more efficient path forward for the benefit of patients. See the meeting agenda and slides here: https://lnkd.in/epxcdyZk #raredisease #MPS #defeatdegeneration
We're pleased to share important progress in our efforts to address the urgent needs of individuals and families with MPS II (Hunter syndrome). Following a recent successful meeting with the FDA's CDER division, we now have a path to accelerated approval and conversion to full approval for tividenofusp alfa (DNL310). This progress, including CDER's recognition of cerebrospinal fluid heparan sulfate (CSF HS) as a surrogate biomarker, reflects a collective effort across the patient community, academia and industry to communicate the science and advocate for faster paths to effective treatments for MPS II. We thank CDER for a positive and collaborative discussion. Additionally, at SSIEM2024 this week, we're presenting new interim data from the Phase 1/2 study of tividenofusp alfa, showing robust and durable biomarker responses and positive effects on clinical endpoints. These results reinforce our commitment to delivering effective therapies as quickly as possible. Read more in our press release here: https://lnkd.in/giQmhav6View our poster presentations here: https://lnkd.in/gYbRTRtQ
We look forward to joining the community at the SSIEM 2024 Annual Symposium next week and to presenting new interim data from the Phase 1/2 study of tividenofusp alfa (DNL310), demonstrating the potential to address both body and brain manifestations of MPS II (Hunter syndrome). We hope to see you there!
What an incredible day coming together with ALS Network to rally support and raise awareness for those living with ALS! A huge thank you to Cytokinetics and all our colleagues who joined us for the third consecutive year at the South San Francisco SPLASH to Cure ALS on August 14th. Coming together, taking the plunge, and standing with the local ALS community was truly inspiring. This month marks the 10th anniversary of the #ALSIceBucketChallenge, making our efforts this year even more impactful—together, we’re making a difference!
We are grateful to Jennifer Thompson and two remarkable young adults for joining us in an important discussion on the impact of ALS on families and the resilience of youth caregivers. Thank you for sharing your experiences with us and for everything Hope Loves Company, Inc. does to support families and children affected by ALS. #ALS #Caregivers #CommunitySupport
Today our Executive Director, Jennifer Thompson and youth program participant, Madeline joined the Denali Therapeutics company for a discussion about youth caregivers and the family impact of #als. Thank you for the invitation to elevate the story of our youngest caregivers and for supporting the community!

Join now to see what you are missing

Join now

Denali Therapeutics | LinkedIn (original) (raw)

About us

Locations

Employees at Denali Therapeutics

Updates

Join now to see what you are missing

Similar pages

Browse jobs

Funding